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methods of prevention and treatment would be clinically desirable since food is an integral part of life, but in some cases it can also be deadly for many people.
Although great progress has been made to elucidate the molecular and cellular basis of allergic disorders, it is not completely understood why some individuals develop allergic sensitization to some foods, while the majority of individuals are immunologically tolerant. In addition, it is yet not fully understood which is the molecular basis involved in the immunopathogenesis of the mechanisms elicited against the food harmless antigens. Once diagnosis of food allergy is achieved and the offending 
allergen or allergenic food is identified, the first clinical or even familial indication is avoidance of the suspected food. Currently, 
there is no definitive treatment for food allergy: the avoidance of food allergens and treatment of food allergen-induced systemic 
reactions with adrenaline remain the standard of care. This implies that the patients and their family should be well educated about precautionary measures to avoid exposure to the responsible allergen, and foods should be adequately labeled in terms of 
allergen content. At present, efforts are being made to develop a disease-modifying therapy. Despite the advances achieved in this 
field in the last decades, there is still no approved immunotherapy 
for food allergies. Since the first report of immunotherapy in 1911 
[1], many efforts have been made by the scientific community 
to optimize efficacy and minimize toxicity. Immunotherapy is at present a treatment procedure to induce, enhance or suppress an immune response in different immunological disorders (cancer, 
autoimmunity, allergy, allorecognition, etc). Although allergen 
specific immunotherapy has been used for the treatment of 
IgE-mediated allergy for more than a hundred years, the first randomized clinical trial of oral immunotherapy for food allergy 
was conducted in 2005 [2]. Of note, this therapeutic procedure, although showing great promise, has not been accepted as a 
routine treatment for food allergy. The induction of adverse 
reactions during treatment, as well as the uncertainty about long-lasting effect after treatment completion, remain as the main drawback of these therapeutic strategies.It is widely accepted that the aim of food allergy immunotherapy is to step-wise induce immune desensitization 
followed by a permanent restoration of oral tolerance. The term 
desensitization accounts for a temporary hypo-responsiveness to the allergen during the regular ingestion of the food, as dosing is discontinued, the protective effect is lost. Tolerance is defined as a prolonged ability to ingest large amounts of food proteins with no detrimental reaction, being immunotherapy completed. In spite of the clinical trials with patients and studies using food allergy mouse models, our understanding of the immune mechanisms underlying food allergy and of how the therapeutic conversion to sustained unresponsiveness take place has not been fully achieved.
Mucosal Vaccines Based on the Hygiene Hypothesis 
PremisesMucosal vaccines exploit the potential of these tissues to induce or enhance the regulatory circuits that affect the local and 
systemic inflammation that undergoes when the immune system 
is exposed to antigenic components. These complex mechanisms 
control the inflammatory process that is elicited against pathogenic microorganisms and avoid immune activation against commensals of the microbiota, food and environmental harmless 
antigens (hypersensitivity), and self antigens (autoimmunity). 
Although these vaccines have been mainly focused for optimal protection against pathogens that infect the host through mucosal surfaces, they constitute a challenging therapeutic procedure for immunopathologies in which restoration of tolerance is critical 
to control aberrant immune activation. Reprogramming T cells through an oral immunotherapy has been successfully achieved in autoimmunity, cancer and alloimmune diseases, being food 
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Food Allergies and the “Old re-Emerging” Treatments
Allergic diseases pose a global and growing health concern 
which has increased worldwide in the last years. Allergy results from a complex interaction between environmental factors and genes. In light of the increase in prevalence and costs of food allergy, both in developed and developing countries, effective 
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allergy on the scope for an efficient tolerance induction that 
suppress the local and systemic memory specific Th2 cells, IgE-producing B cells and innate cells such as basophils, mast cells, eosinophils and type 2 innate lymphoid cell. 
The delivery of antigens through the gastrointestinal tract remains a major challenge due to unfavorable physiological 
conditions (pH and enzymes) and significant gastrointestinal 
biological barriers, which restrict the uptake of antigens. To 
improve mucosal vaccine efficiency and delivery, several mucosal adjuvants and bioadhesive delivery systems are being investigated and numerous advantages, including protection from degradation, increasing concentration of antigen in the vicinity of mucosal tissue for better absorption, extending their residence time, and/or targeting them to sites of antigen uptake, have been proposed. 
The use of pharmacological, immunological or microbe-derived adjuvants in human mucosal vaccines to enhance the recipient’s immune response to a supplied immunogen, while keeping the injected foreign material at minimum, constitutes a challenge 
[3,4]. Mucosal vaccines that deviate the allergen-specific Th2 
cells, which are central for atopy, into allergen-specific regulatory 
T cells (Treg), which mediate desensitization and tolerance, may offer a potential treatment for food allergy.
Since Treg are pivotal controllers of innate and adaptive 
immune responses that govern inflammation in allergic 
diseases, and impaired Treg numbers, homing properties and/or 
functioning have been associated with allergies [5,6]. Treg subsets 
have become frequently investigated as targets for more specific 
immunotherapy. Particularly, antigen-specific targeting of Treg would enable local and tailor made interventions, while obviating the negative side effect of general immunosuppression. In this respect, the restoration of tolerance in allergic patients may constitute a therapeutic strategy to revert allergic symptoms and 
the underlying Th2-mediated immunologic mechanisms that may potentially induce life-threatening reactions, such as anaphylaxis, upon exposure to the allergen. 
The Hygiene Hypothesis premises give rise to the fundamental 
basis for modulatory or tolerogenic immunotherapies. Although it may still be debatable, this hypothesis states that the germfree life style of the developed or westernized countries has promoted control of the main chronic infectious diseases, such as measles, 
TBC, hepatitis, etc, while it has induced a marked rise in the 
incidence of immunopathologies such as Type 1 diabetes, 
Crohn´s disease, asthma, food allergy, multiple sclerosis, etc. This 
observation, firstly stated by Stracham et al. [7], and then modified by Bach et al. [8], has led us to understand or interpret the rise in the incidence of asthma, hay fever, atopic dermatitis, food allergy, etc 
witnessed during the last decades. This epidemiologic shift could be attributed to gene-environment interactions, and to changes in the exposure to pathogenic and commensal microorganism, mainly in early life, which have had an impact on the dynamic and 
reversible epigenetic modification of human genome. Changes in gene activity or gene regulation facilitate the adaptation of a cell to the environment but it may also increase the risk of 
chronic inflammatory diseases (cancer, autoimmunity, allergy, 
metabolic syndrome, etc). Understanding this complex gene-environment interaction will allow us to develop novel generation of treatments that could modify aberrant immune activation and 
chronic diseases. Based on theses premises the use of Th1 pro-
inflammatory [9,10] or immunosuppressant components [11,12] may compensate the deprived immune stimulation and promotion 
of counter-regulatory circuits that control the Th2-mediated immunity that governs allergic diseases. However, it is currently 
suspected that not only can microorganism exposure influence the development of the complex immunoregulatory circuits at mucosal sites, but diet and microbiota-derived metabolites are also implicated.
As mentioned before, several reports have demonstrated that tolerance is impaired in allergic patients and that upon 
active immunotherapy Tregs are expanded [13,14], and FoxP3 
is epigenetically controlled [15,16]. Subsequently, expanded 
Tregs can control other cells such as innate (ILC2, dendritic 
cells, basophils and mast cells) and adaptive cells (T and B cells), and the allergic reaction. Hopefully our better understanding of epigenetics will increase our possibilities to develop pro-active treatments to prevent, ameliorate or revert allergy.
Immunotherapies for Food Allergy
Allergen immunotherapy (also called allergy vaccine therapy) involves the administration of gradually increasing quantities of 
specific allergens to patients with IgE-mediated conditions with no subsequent clinical reaction upon further natural exposure to the allergen. Due to the fact that proteins and glycoproteins previously used in allergen immunotherapy were extracted from natural sources such as pollens, molds, pelt, insect venoms and 
foods, they were originally called allergen extracts. In 1998, 
the World Health Organization (WHO) proposed the term “allergen vaccine” to replace “allergen extract,” since allergen 
immunotherapy is an immune modifier as are vaccines, and are 
currently performed with purified or recombinant components. Given that many components in the natural source endow 
adjuvant properties to the allergen extract, the use of purified components in vaccine should be accompanied by additional adjuvants to achieve a directed and more effective induction of immune response.
Although it has been demonstrated in several approaches for food allergy immunotherapy that desensitization is achievable 
using purified allergens, and that patients can tolerate higher doses of allergen while continuing with treatment, the use of additional components with adjuvant capacity is being explored 
to enhance its immunomodulatory effect. The use of native, 
modified ore fragments of allergens containing either B or T 
epitopes with adjuvants (Th1- or tolerogenic-adjuvants), drugs 
(corticoids, rapamycin, cytokines, etc) or natural products, such 
as the nonspecific Chinese herbals, combined with mucosal delivery routes may have a positive impact on the outcome of immunotherapy for food allergy. Nevertheless, minimizing adverse reactions, and sustaining a prolonged immunoregulatory effect that promotes clinical tolerance after treatment is 
completed and controlled allergen exposure is discontinued; still remain as the major unmet needs for these disease-modifying treatments. In mechanistic terms the establishment of sustained 
immune tolerance implies the induction of memory Tregs that 
control memory Th2 and B cells in the absence of regular allergen 
exposure. This active process is evolutionary induced in the gut-
associated lymphoid tissue (GALT), where CX3CR+ macrophages and CD103+ tolerogenic dendritic cells are critical to coordinately 
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sample food antigens from the lumenal intestine, or antigens 
translocated into the lymphoid follicules, and induce Tregs from 
naïve T cells in the mesentheric draining lymph nodes [17]. As 
previously mentioned, Tregs are impaired in patients with food allergy, and following oral immunotherapy in peanut allergic patients, oral tolerance is achieved with hypomethylation of 
the Treg-specific demethylated region in FOXP3 locus, with the subsequent chromatin accessibility and transcription of this 
critical factor that endows T cell with regulatory functions [18]. 
These Tregs behave as conventional effector T cells, and exert critical regulatory mechanisms through which they control the 
different stages of an immune response. Therefore, it has been shown that an effective tolerogenic immunotherapy is associated 
with the expansion of mucosal IL-10- and/or TGF-β-secreting 
FOXP3+ Treg and the development of unresponsiveness to allergen exposure, both in patients and experimental animal models 
[18,19]. However, additional cells or cell subsets may be involved in the resolution of food allergy (regulatory ILC, regulatory B cells, 
regulatory dendritic cells, etc).Immunotherapy protocols that have showed promise to desensitize individuals to food allergens represents tremendous progress in treating food allergy, however much effort is required to develop immunotherapies with a long-lasting tolerance induction. Desensitizing immunotherapy is generally delivered orally, sublingually or through the skin.
Oral ImmunotherapySome studies have shown hopeful results for oral 
immunotherapy (OIT) with milk, peanut and egg allergens. However, the risk of severe reactions during allergen 
administration is of concern [20,21]. (OIT) consists of a daily consumption of milligrams to grams of the selected allergen, which is incrementally raised over weeks to months with the goal 
of inducing desensitization and then tolerance [22-24]. In the first 
randomized double-blind placebo-controlled OIT trial performed 
by Skripak et al. [24] children with IgE-mediated cow’s milk 
allergy were randomized given milk or placebo. The main point of this study was that patients tolerated 128 times higher amounts of milk compared with patients before treatment or with placebo-
treated patients [24], although patients experienced transient 
adverse reactions after OIT treatment. Keet et al. [25] showed 
tolerance in 40 % of subjects receiving milk OIT who passed an oral food challenge when treatment was ceased for 6 weeks [26], 
while, in other study, three to five years after OIT with milk was 
completed, 25% of patients consumed normal amounts of milk 
without any symptoms, and 20% of treated patients experienced 
anaphylactic reactions during the follow-up period [25]. Similar 
results were observed in OIT with egg and peanut allergens 
in non anaphylactic children [27]. These findings suggest that optimization is needed and further studies are mandatory for a complete understanding of therapy to achieve a long-term tolerance. 
A relatively new form of non-specific immunotherapy for food allergy is the anti-IgE therapy (with humanized anti-IgE 
monoclonal antibody-Omalizumab), which has been successfully used in asthma. Sampson et al. started a phase II clinical trial 
with Omalizumab in 150 patients with peanut allergy; however, the study was terminated early due to the severe reactions 
that occurred during the peanut challenge [28]. Recently, a combination therapy was studied using the anti-IgE antibody in 
patients undergoing OIT. Subjects with history of milk anaphylaxis received Omalizumab prior to rapid high-dose initial escalation 
phase (one day) of orally administered milk, followed by a slower 
dose escalation (few days and weeks) when Omalizumab was 
discontinued. Although an enhanced frequency of natural or milk-
specific Treg was not evidenced, cell proliferation of milk-specific 
T cells was consistently abrogated and a plausible explanation 
was that anergy was induced in memory T cells through a 
somehow IL-10- and TGF-β-independent mechanism. An increase 
in IFN-γ/IL-4 and IFN- γ /IL-13 ratios were uniformly evidenced, 
thus suggesting that immunomodulation was involved. This novel treatment was probed to be effective at inducing immunological desensitization, and patients tolerated more than 200ml of 
daily intake milk. This study may reflect original findings in experimental animal models which stated that oral tolerance with high doses of antigen administration produced exhaustion of 
T cells, while low dose administration enhanced Foxp3+ Treg [29].
Despite the number of promising OIT studies and the increasing interest of the medical community in the development of a routine 
OIT, a percentage of patients still suffer from adverse side effects. 
The use of monoclonal antibodies specific for IgE combined with 
OIT has been explored to increase safety, allowing the immune system to be desensitized to food allergens more quickly and 
safely than OIT alone. Nevertheless, this protocol should be further optimized to achieve a sustained desensitization during dose maintenance or tolerance induction upon natural diet is resumed.
Although OIT is not FDA approved, studies have consistently found that clinical desensitization is possible with current protocols, while some variables should still be optimized or 
modified (optimal delivery carriers, novel adjuvants, pure 
native, recombinant or modified allergenic proteins, etc) to achieve sustained tolerance with minimal adverse reactions and maximum adherence.
Sublingual Immunotherapy
Sublingual immunotherapy (SLIT) involves frequent placement of less than micrograms of allergen in solution or in dissolving tablets under the tongue, where it is held for 
several minutes before spitting out or swallowing. Then, a daily allergen doses with gradually increasing amount of allergen over a period of days or weeks is administered [30]. Cochrane 
analyses have confirmed the efficacy and safety of sublingual 
therapy for allergic rhinitis with long-term benefits (1-2 years) 
[31]. The first reported double-blind, placebo-controlled clinical trial using the sublingual route for food allergy was done by 
Enrique et al. [2]. Although most of the SLIT studies have focused 
on inhalant allergies, emerging clinical trials with SLIT have shown promising results at inducing desensitization in food 
allergy [32,33]. However, SLIT is not currently recommended 
for treatment of food allergy [34]. Only few studies have been 
done in peanut, nuts, kiwi, peach and cow´s milk allergy [35-
39], and they showed lower frequencies of adverse reactions 
compared with OIT, which is likely due to lower doses of allergen administration and the capacity of the mouth mucosa to induce 
intestinal tolerance. However, the efficacy of SLIT is still debated 
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and characterization of regulatory cells and mechanisms at the 
buccal mucosa are emerging [40]. Considering that the induction 
of Treg is the key mechanism underlying desensitization and 
tolerance, it has been reported that the current protocols of SLIT 
have a lower efficiency as compared to OIT [30,41]. Nevertheless, 
SLIT protocols used for egg, cow´s milk or peanut allergy [42] 
showed a significant increase in the threshold dose of the food 
allergen to induce allergic symptoms, a decrease in serum specific 
IgE along with a rise in serum IgG4 levels , and induction of Tregs 
[43]. There are only two randomized studies comparing oral 
and sublingual immunotherapies. Keet et al., found in a clinical 
trial with 30 milk allergic patients comparing SLIT alone versus 
SLIT followed by OIT, that similar number of total adverse food reactions were elicited between groups, however, the frequency 
of systemic reaction was higher in OIT groups. Of note, the oral challenge performed after 60 weeks of maintenance doses, 
rendered a higher allergen threshold in SLIT followed by OIT 
treated patients compared with SLIT-treated patients [26,44]. 
Narisety et al. [44] performed a similar randomized study with 
peanut allergic patients to compare the safety and efficacy of 
OIT and SLIT. They found a partial desensitization with at least a 10-fold increases in peanut challenge threshold compared with 
baseline. They similarly found that efficacy of OIT was greater 
than SLIT, although safety is still greater in patients receiving SLIT 
compared with OIT [44]. 
In summary, SLIT for milk and peanut has been clearly associated with a substantially reduced risk and severity of 
adverse reactions, although efficacy and long-term effectiveness are the main drawbacks.  Subcutaneous and Epicutaneous Immunotherapy 
The major form of allergen-specific immunotherapy is 
the subcutaneous immunotherapy (SCIT), which involves the 
subcutaneous injection of the allergen. Although, it is widely used for treatment of allergy, it is not accepted as a routine therapy, especially for children with food allergy. Recruitment of patients 
and then (less that 5% of all allergic patients) adherence to 
SCIT (less than 25% of patients drop out within the first year of 
treatment) are difficult to achieve [45]. SCIT has proved efficacy in 
respiratory allergy with comparable results to SLIT. Nevertheless, 
clinical trials of SCIT in peanut allergic patients showed that anaphylactic side-effects induced during the administration of 
the native allergen are highly frequent [46,47]. The first attempt 
to improve this protocol was done by The European multicenter 
consortium that conducts the prospective Food Allergy Specific 
Immunotherapy (FAST) project to evaluate the use of alum-
adsorbed hypoallergens to control fish and peach allergy. Recombinant mutated allergens, with decreased IgE-binding 
capacity and intact T cell-reactivity capacity, were included in 
the SCIT. Patients will be enrolled for a phase I/IIA initial clinical trial, while animal models will be used to evaluate the allergenicity of the recombinant hypoallergenic proteins developed and 
efficacy of the immunotherapy [48]. New routes of skin administration were explored and the epicutaneous administration has been more recently investigated 
in food allergy. Epicutaneous immunotherapy (EPIT) with 
micrograms of allergen-embedded patch daily administration has 
been carried out. One of the first clinical trials for EPIT evaluated 18 children with cow´s milk allergy during three months. 
Although EPIT showed no serious systemic adverse effects, only local pruritus and discomfort was reported with no compromise 
of patient adherence to the treatment [49]. Phase I [50], phase 
IIa [51,52] and phase III [53] clinical trials conducted with peanut allergic patients showed that only mild to moderate local reactions were elicited with induction of desensitization, and an increase in cumulative reactive allergen-dose from baseline. Sampson et al demonstrated using an adjuvant-free mouse model of food allergy that the epicutaneous administration of an allergen 
induced a particular gut-homing of FOXP3+ TGF-β-producing Treg that suppressed experimental anaphylaxis. 
Although EPIT seems to be the less efficacious immunotherapy to achieve desensitization, this route of delivery seems to have 
fewer and less intense side effects than OIT, with no systemic reaction, and patients prefer wearing a skin patch to orally consuming the same food allergen each day. 
ConclusionOur understanding of the immunobiology of food allergy still remains to be completed. Great efforts are being made to develop novel strategies in animal models exploring combination of 
mucosal routes [54], bioadhesive carrier systems [34,55], novel 
immunomodulatory and/or tolerogenic adjuvants [9,10,55,56], 
immunological drugs to expand Tregs [12] and nanoparticles [56] 
to prevent or revert food allergy. These finding will undoubtedly provide new parameters to analyze the induction of novel regulatory cell subsets, and cellular and molecular biomarkers for regulatory cell activation, with a direct impact in the design 
of safer and more effective treatments. Defining markers for 
tolerance induction are critical for clinical trials. Although the traditional standard of care has been allergen avoidance, there is recent progress in using allergen exposure to induce desensitization in patients. It is to be hoped that in the near future sustained unresponsiveness following the natural exposure of food, without requiring continued exposure to the food allergen, will be achieved with novel and promising disease-modifying immunotherapies.
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